Biological Sciences and Healthcare, part 4

... > Body structure > Morphologically altered structure > Morphologic abnormality > Growth alteration > Proliferation > Proliferative mass (morphologic abnormality) > Neoplasm and/or hamartoma (morphologic abnormality) > Tumor > Malignant Neoplasm (Morphology) > Malignant hematopoietic neoplasm (morphologic abnormality) > leukaemia > Myeloid leukaemia > Acute myeloid leukemia (morphologic abnormality) > Therapy-related acute myeloid leukemia, epipodophyllotoxin-related > Therapy-related acute myeloid leukemia and myelodysplastic syndrome, topoisomerase type II inhibitor-related type (morphologic abnormality)

... > Body structure > Morphologically altered structure > Morphologic abnormality > Lesion, NOS > Mass > Proliferative mass (morphologic abnormality) > Neoplasm and/or hamartoma (morphologic abnormality) > Tumor > Malignant Neoplasm (Morphology) > Malignant hematopoietic neoplasm (morphologic abnormality) > leukaemia > Myeloid leukaemia > Acute myeloid leukemia (morphologic abnormality) > Therapy-related acute myeloid leukemia, epipodophyllotoxin-related > Therapy-related acute myeloid leukemia and myelodysplastic syndrome, topoisomerase type II inhibitor-related type (morphologic abnormality)

... > Body structure > Morphologically altered structure > Morphologic abnormality > Growth alteration > Proliferation > Proliferative mass (morphologic abnormality) > Neoplasm and/or hamartoma (morphologic abnormality) > Tumor > Hematopoietic neoplasm (morphologic abnormality) > Malignant hematopoietic neoplasm (morphologic abnormality) > leukaemia > Myeloid leukaemia > Acute myeloid leukemia (morphologic abnormality) > Therapy-related acute myeloid leukemia, epipodophyllotoxin-related > Therapy-related acute myeloid leukemia and myelodysplastic syndrome, topoisomerase type II inhibitor-related type (morphologic abnormality)

... > Body structure > Morphologically altered structure > Morphologic abnormality > Lesion, NOS > Mass > Proliferative mass (morphologic abnormality) > Neoplasm and/or hamartoma (morphologic abnormality) > Tumor > Hematopoietic neoplasm (morphologic abnormality) > Malignant hematopoietic neoplasm (morphologic abnormality) > leukaemia > Myeloid leukaemia > Acute myeloid leukemia (morphologic abnormality) > Therapy-related acute myeloid leukemia, epipodophyllotoxin-related > Therapy-related acute myeloid leukemia and myelodysplastic syndrome, topoisomerase type II inhibitor-related type (morphologic abnormality)

... > Body structure > Morphologically altered structure > Morphologic abnormality > Growth alteration > Proliferation > Proliferation of hematopoietic cell type (morphologic abnormality) > Myeloproliferative disorder (morphologic abnormality) > Myeloid neoplasm (morphologic abnormality) > Myeloid leukaemia > Acute myeloid leukemia (morphologic abnormality) > Therapy-related acute myeloid leukemia, epipodophyllotoxin-related > Therapy-related acute myeloid leukemia and myelodysplastic syndrome, topoisomerase type II inhibitor-related type (morphologic abnormality)

... > Body structure > Morphologically altered structure > Morphologic abnormality > Growth alteration > Proliferation > Proliferative mass (morphologic abnormality) > Neoplasm and/or hamartoma (morphologic abnormality) > Tumor > Hematopoietic neoplasm (morphologic abnormality) > Myeloid neoplasm (morphologic abnormality) > Myeloid leukaemia > Acute myeloid leukemia (morphologic abnormality) > Therapy-related acute myeloid leukemia, epipodophyllotoxin-related > Therapy-related acute myeloid leukemia and myelodysplastic syndrome, topoisomerase type II inhibitor-related type (morphologic abnormality)

... > Body structure > Morphologically altered structure > Morphologic abnormality > Lesion, NOS > Mass > Proliferative mass (morphologic abnormality) > Neoplasm and/or hamartoma (morphologic abnormality) > Tumor > Hematopoietic neoplasm (morphologic abnormality) > Myeloid neoplasm (morphologic abnormality) > Myeloid leukaemia > Acute myeloid leukemia (morphologic abnormality) > Therapy-related acute myeloid leukemia, epipodophyllotoxin-related > Therapy-related acute myeloid leukemia and myelodysplastic syndrome, topoisomerase type II inhibitor-related type (morphologic abnormality)

... > Body structure > Morphologically altered structure > Morphologic abnormality > Growth alteration > Proliferation > Proliferative mass (morphologic abnormality) > Neoplasm and/or hamartoma (morphologic abnormality) > Tumor > Malignant Neoplasm (Morphology) > Malignant hematopoietic neoplasm (morphologic abnormality) > leukaemia > Acute leukemia > Acute myeloid leukemia (morphologic abnormality) > Therapy-related acute myeloid leukemia, epipodophyllotoxin-related > Therapy-related acute myeloid leukemia and myelodysplastic syndrome, topoisomerase type II inhibitor-related type (morphologic abnormality)

... > Body structure > Morphologically altered structure > Morphologic abnormality > Lesion, NOS > Mass > Proliferative mass (morphologic abnormality) > Neoplasm and/or hamartoma (morphologic abnormality) > Tumor > Malignant Neoplasm (Morphology) > Malignant hematopoietic neoplasm (morphologic abnormality) > leukaemia > Acute leukemia > Acute myeloid leukemia (morphologic abnormality) > Therapy-related acute myeloid leukemia, epipodophyllotoxin-related > Therapy-related acute myeloid leukemia and myelodysplastic syndrome, topoisomerase type II inhibitor-related type (morphologic abnormality)

... > Body structure > Morphologically altered structure > Morphologic abnormality > Growth alteration > Proliferation > Proliferative mass (morphologic abnormality) > Neoplasm and/or hamartoma (morphologic abnormality) > Tumor > Hematopoietic neoplasm (morphologic abnormality) > Malignant hematopoietic neoplasm (morphologic abnormality) > leukaemia > Acute leukemia > Acute myeloid leukemia (morphologic abnormality) > Therapy-related acute myeloid leukemia, epipodophyllotoxin-related > Therapy-related acute myeloid leukemia and myelodysplastic syndrome, topoisomerase type II inhibitor-related type (morphologic abnormality)

... > Body structure > Morphologically altered structure > Morphologic abnormality > Lesion, NOS > Mass > Proliferative mass (morphologic abnormality) > Neoplasm and/or hamartoma (morphologic abnormality) > Tumor > Hematopoietic neoplasm (morphologic abnormality) > Malignant hematopoietic neoplasm (morphologic abnormality) > leukaemia > Acute leukemia > Acute myeloid leukemia (morphologic abnormality) > Therapy-related acute myeloid leukemia, epipodophyllotoxin-related > Therapy-related acute myeloid leukemia and myelodysplastic syndrome, topoisomerase type II inhibitor-related type (morphologic abnormality)